The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes

Bortezomib (BTZ) is a first-in-class proteasome inhibitor approved for the therapy of multiple myeloma that also displays unique regulatory activities on immune cells. The enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan metabolizing enzyme exerting potent immunoregulatory effects when ex...

詳細記述

保存先:
書誌詳細
出版年:Front Immunol
主要な著者: Mondanelli, Giada, Albini, Elisa, Pallotta, Maria T., Volpi, Claudia, Chatenoud, Lucienne, Kuhn, Chantal, Fallarino, Francesca, Matino, Davide, Belladonna, Maria L., Bianchi, Roberta, Vacca, Carmine, Bicciato, Silvio, Boon, Louis, Ricci, Giovanni, Grohmann, Ursula, Puccetti, Paolo, Orabona, Ciriana
フォーマット: Artigo
言語:Inglês
出版事項: Frontiers Media S.A. 2017
主題:
Immunology
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5390013/
https://ncbi.nlm.nih.gov/pubmed/28450863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2017.00428
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料